TD Cowen analyst Ritu Baral reiterated a Buy rating on Pliant Therapeutics (NASDAQ: PLRX).The analyst commented, "Positive Ph2a 24wk INTEGRIS-PSC ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE